GoldenGolden
Advanced Search
Exicure

Exicure

Exicure is a Chicago, Illinois-based biotechnology company that was founded in 2011.

Exicure is a biotech company that develops nucleic acid-based therapeutics to treat rare and severe genetic diseases and cancer. The company has an SNA technology that enables the delivery of genetically-targeted therapies to a broad range of tissues and cells.

Timeline

August 31, 2018
Exicure raises a $22,000,000 venture round.
September 27, 2017
Exicure raises a $20,000,000 venture round from AbbVie Biotech Ventures, Craig Mundie, David R. Walt, Katalyst Securities, Mark Tompkins, Patrick G. Ryan and Tempus Labs.
September 6, 2017
Exicure raises a $11,200,000 venture round from Alumni Ventures Group, HT Capital, Knoll Capital Management and Luye Pharma.
June 17, 2017
Exicure raises a $13,600,000 series C round from Bill Gates, Boon Hwee Koh, Craig Mundie and Patrick Ryan.
October 21, 2015
Exicure raises a $14,800,000 venture round from Liz Lefkofsky and Tempus Labs.
February 5, 2015
Exicure raises a $4,500,000 series C round.
December 21, 2011
Exicure raises a $5,400,000 series B round from Abbott Biotech Ventures, Craig Mundie, David R. Walt, Eric Schmidt and Patrick Ryan.
December 1, 2009
Exicure raises a $2,500,000 series A round.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 13, 2021
BioSpace
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNATM) technology, today announced the appointment of Brian C. Bock as the Company's Chief Financial Officer (CFO) effective immediately.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.